GRDN NYSE Week ended 31 Jul 2026

Weekly Investor Report

Guardian Pharmacy Services, Inc. · Healthcare · Medical Care Facilities

Open interactive chart View report data
Latest close 39.53 USD
-2.3% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 8.0% above the Trend Line and sits at 81.9% of its 52-week range. The latest completed week returned -2.3%, after a -5.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. Options positioning is mixed with 38/100 conviction, while the latest news-sentiment score is 63/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 58 out of 100
Latest Close 39.53 USD 31 Jul 2026
1W Return -2.3% latest completed week
4W Return -5.9% short-term follow-through
12W Return 9.5% quarterly tape
Trend Breadth 96.2% 50 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 50-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Activity pressure is negative, which weakens the current setup.
  • 14 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.3% Latest completed week; four-week move -5.9%. Indicator stack 98/34 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 38/100 conviction; expected move 14.0%. News sentiment 63/100 51 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 8.0% above the Trend Line and sits at 81.9% of its 52-week range. The latest completed week returned -2.3%, after a -5.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9612-week average 0.98

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.96Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1414 reversal markers

No recent accumulation markers. 14 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -5.9% over four weeks, 9.5% over 12 weeks, and 94.4% over one year. The current trend has remained active for 50 consecutive weeks.

Performance by holding period

1W-2.3%
4W-5.9%
12W9.5%
26W30.9%
52W94.4%
Active trend streak50 weeks
Active weeks in one year50
Trend breadth96.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.33Latest activity-pressure read.
Pressure change-125.5%Four-week change in activity pressure.
Leadership11.85Latest relative-leadership reading.
RS change-49.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength43/100Blend of value, momentum, and quality. Underlying universe rank 58; rank 1 is best.
Value6/100Relative valuation strength. Underlying universe rank 95; rank 1 is best.
Quality79/100Profitability and accounting quality. Underlying universe rank 22; rank 1 is best.
Momentum94/100Medium-term price momentum. Underlying universe rank 7; rank 1 is best.
Growth85/100Revenue and earnings growth. Underlying universe rank 16; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
48.3x
Price divided by trailing earnings.
Price / sales
1.8x
Market value relative to trailing revenue.
EV / EBITDA
24.9x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
4.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
20.9%
Gross profit retained from each unit of revenue.
Operating margin
5.4%
Operating profit retained from revenue.
Free-cash-flow margin
7.4%
Free cash flow generated from revenue.
Return on invested capital
27.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
13.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
26.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

GRDN shows mixed options pressure with a 38/100 conviction score, put-call volume ratio of 1.50, expected move of 14.0%, and Sharemaestro trend signal active.

Conviction38/100
Expected move14.0%
Put/call volume1.50
Pressure-13
Speculation4
Volatility79
Trend agreement92
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment63/100

Weighted news tone is positive across 51 relevant articles.

27 positive · 24 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move14.0%Nearest-chain priced movement where available.
52-week drawdown-10.2%Distance below the 52-week high.
13-week volatility3.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+12.2%Week of 6 Feb.
Worst week-5.2%Week of 6 Mar.
Latest week-2.3%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains6
Flat weeks0
Modest losses11
Sharp losses3
Recent vol3.0%13-week weekly-return volatility.
Base vol5.9%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew5.4% / -3.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape63/100

Trend, activity pressure, participation, and risk combine to a 63/100 tape read.

 Indicator analysis81/100

Latest 12-week confirmation: trend 12/12, activity pressure 11/12, relative leadership 12/12.

Activity pressure 0.96; 14 reversal markers Factors54/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 64; Small Cap Core rank 96 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options58/100

GRDN shows mixed options pressure with a 38/100 conviction score, put-call volume ratio of 1.50, expected move of 14.0%, and Sharemaestro trend signal active.

Mixed · Options-market disagreement · Expected move 14.0% Sentiment63/100

Weighted news tone is positive across 51 relevant articles.

Guardian Pharmacy Services Inc (GRDN) Cash Flow Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202639.53 USD-2.3%36.60 USD27.29 USD-0.3311.851.4MOn
24 Jul 202640.45 USD-0.2%36.26 USD27.16 USD0.1816.651.6MOn
17 Jul 202640.52 USD-1.1%35.94 USD27.02 USD0.6317.231.4MOn
10 Jul 202640.96 USD-2.5%35.64 USD26.88 USD1.0217.741.8MOn
3 Jul 202642.00 USD-0.7%35.28 USD26.73 USD1.3023.472.7MOn
26 Jun 202642.31 USD-0.2%34.87 USD26.56 USD1.1928.302.9MOn
19 Jun 202642.41 USD-1.6%34.44 USD26.39 USD0.9526.781.9MOn
12 Jun 202643.09 USD6.4%33.97 USD26.21 USD0.7631.281.6MOn
5 Jun 202640.48 USD4.5%33.51 USD26.02 USD0.4725.382.2MOn
29 May 202638.74 USD0.7%33.12 USD25.86 USD0.4118.031.6MOn
22 May 202638.48 USD5.1%32.76 USD25.71 USD0.5719.731.9MOn
15 May 202636.61 USD1.4%32.43 USD25.56 USD0.7515.591.8MOn
8 May 202636.09 USD-3.4%32.04 USD25.43 USD1.0214.582.8MOn
1 May 202637.37 USD-0.5%31.62 USD25.30 USD1.2521.601.5MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.